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Abstract
Purpose
The tumor biology of metastatic breast cancers differ according to the metastatic sites, and
the features of cancer metabolism may also be different. The aim of this study is to investi-
gate the expression of lipid metabolism-related proteins in metastatic breast cancer accord-
ing to metastatic site and discuss the clinical significance thereof.
Methods
Immunohistochemical staining for lipid metabolism-related proteins [fatty acid synthase
(FASN), hormone-sensitive lipase (HSL), carnitine palmitoyltransferase IA (CPT-1A), acyl-
CoA oxidase 1 (ACOX1), fatty acid binding protein 4 (FABP4,) and perilipin 1 (PLIN1)] was
performed using a tissue microarray of 149 cases of metastatic breast cancer (bone metas-
tasis = 39, brain metastasis = 37, liver metastasis = 21, and lung metastasis = 52).
Results
The expression levels of ACOX1 (p = 0.009) and FASN (p = 0.007) varied significantly
according to metastatic site, with the highest expression in brain metastasis and the lowest
expression in liver metastasis. ACOX1 positivity (p = 0.005) and FASN positivity (p = 0.003)
correlated with HER-2 positivity. The expression of FASNwas significantly higher in HER-2
type breast cancer, and lower in luminal A and TNBC type breast cancer (p<0.001). Among
lipid metabolism-related proteins, PLIN1 positivity was found to be an independent poor prog-
nostic factor on multivariate analysis (Hazard ratio: 4.979, 95% CI: 1.054–22.59, p = 0.043).
Conclusion
Different expression levels of lipid metabolism-related proteins were observed according to
metastatic site. The expression of ACOX1 and FASN was highest in brain metastasis.
These results suggest that the metastatic site should be considered when using lipid metab-
olism inhibitors for targeted therapy.
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Introduction
Breast cancer has a high mortality and morbidity, and distant metastasis is often responsible
for the high mortality and morbidity. The major distant metastatic sites of breast cancer are
lung, bone, brain, and liver [1,2], and among those, bone and brain metastases [3–8] are the
most investigated. Multiple factors affect cancer progression, but the reciprocal interactions
between tumor cells and host tissue are essential. Therefore, the interaction of cancer cells and
distant organ tissue is expected to be important in distant metastasis.
The “seed and soil” hypothesis has been proposed for cancer metastasis, as specific carcino-
mas exhibit characteristic metastatic patterns. Breast cancer also exhibits unique characteristics
according to its metastatic sites. Brain metastasis is associated with estrogen receptor (ER) neg-
ativity, HER-2/EGRF overexpression, and basal subtype [5–7], whereas bone metastasis is asso-
ciated with ER positivity, and ER positivity/progesterone receptor (PR) negativity [4,9,10].
In tumors, a metabolic shift in energy production occurs, from oxidative phosphorylation
in normal cells towards aerobic glycosis in cancer cells, which is called the Warburg effect [11].
However, different metabolic mechanisms may be used for energy production depending upon
the tumor type [12]. One of these metabolic pathways is lipid metabolism; it includes lipid syn-
thesis, lipid degradation and catabolism, and fatty acid (FA) oxidation. Fatty acid synthase
(FASN) is one enzyme that is involved in lipid synthesis [13], whereas hormone-sensitive lipase
(HSL) [13–15] is involved in lipid degradation and catabolism. Carnitine palmitoyltransferase
IA (CPT-1A) and acyl-CoA oxidase 1 (ACOX1) are major enzymes involved in FA oxidation
[16–18]. In addition, lipid transport and uptake is also an important process in lipid metabo-
lism in cancer. Proteins involved in this process include fatty acid binding protein 4 (FABP4)
and perilipin 1 (PLIN1) [19]. Because metastatic breast cancer exhibits unique characteristics
depending upon its metastatic organs, it is reasonable to assume that they have different meta-
bolic features, but this subject has rarely been studied thus far. This study aims to investigate
variation in the expression of lipid metabolism-related proteins in different metastatic sites,
and to discuss its clinical significance.
Materials and Methods
Patient selection
This study was approved by the Institutional Review Board (IRB) of Severance Hospital. The
informed consent form was waived by IRB. Patient records/information was anonymized and
de-identified prior to analysis. Patients with invasive primary breast cancer and metastasis to
distant organs (lung, bone, brain, and liver) were selected from medical records of the Depart-
ment of Pathology of Severance Hospital. Only patients with a diagnosis of invasive ductal car-
cinoma were included. In total, 149 cases were identified, and 36 cases were paired between
primary cancer and metastatic cancer. All slides were reviewed, and pathologic diagnoses were
approved by two pathologists (JSK andWHJ). Histological grade was assessed using the Not-
tingham grading system [20].
Tissue microarray
Representative areas were selected on the H&E-stained slides of the tumors, and the corre-
sponding spots were marked on the surfaces of the corresponding paraffin blocks. Using a
biopsy needle, a 3-mm tissue core in the selected area was punched out and placed onto a 6 × 5
recipient block. Two tissue cores were extracted to minimize extraction bias. Each tissue core
was assigned a unique tissue microarray location number that was linked to a database contain-
ing other clinicopathologic data.
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Immunohistochemistry (IHC)
The antibodies used for IHC in this study are shown in Table 1. Formalin-fixed, paraffin-
embedded (FFPE) tissue samples were used as follows. Three-micron-thick slices from the
FFPE tissue blocks were deparaffinized and rehydrated in xylene and alcohol solutions and
stained using a Ventana Discovery XT automated stainer (Ventana Medical Systems, Tucson,
AZ, USA). Antigen retrieval was performed with CC1 (Cell Conditioning 1) buffer (citrate
buffer pH 6.0, Ventana Medical Systems). Appropriate positive and negative controls were
used.
Interpretation of immunohistochemical results
A cut-off value of 1% or higher positively-staining nuclei was used to define ER- and AR-posi-
tivity [21]. HER-2 staining was analyzed according to the American Society of Clinical Oncol-
ogy (ASCO)/College of American Pathologists (CAP) guidelines using the following
categories: 0 = no immunostaining; 1+ = weak incomplete membranous staining, less than
10% of tumor cells; 2+ = complete membranous staining, either uniform or weak in at least
10% of tumor cells; and 3+ = uniform intense membranous staining in at least 30% of tumor
cells [22]. HER-2 staining was considered positive when strong (3+) membranous staining was
observed, whereas it was considered negative when no or weak (0 to 1+) staining was noted.
The status of all immunohistochemical markers was determined using light microscopy to
assess fractions of stained cells. HSL, PLIN1, FABP4, CPT-1A, ACOX1, and fatty acid synthase
(FASN) immunostaining were scored as the product of the proportion of stained cells (0 = no
staining, 1 = less than 30%, or 2 = more than 30%) and staining intensity (0 = no staining,
1 = weak, 2 = moderate, or 3 = strong). A total score of 2–6 was considered positive, while a
score of 0 or 1 was considered negative [23].
Tumor phenotype classification
In this study, breast cancer phenotypes were classified according to IHC results for ER, PR,
HER-2, and Ki-67, as well as FISH results for HER-2 as follows [24]: luminal A type: ER and/or
PR positive, HER-2 negative, and Ki-67 LI<14%; luminal B type: (HER-2 negative) ER and/or
PR positive, HER-2 negative, and Ki-67 LI14%, or (HER-2 positive) ER and/or PR positive
and HER-2 overexpressing and/or amplified; HER-2 type: ER and PR negative and HER-2
Table 1. Source, clone, and dilution of antibodies used in this study.
Antibody Clone Catalog number Dilution Company
Molecular subtype-related
ER SP1 RM-9101-S 1:100 Thermo Scientiﬁc, CA, USA
PR PgR 636 M3569 1:50 DAKO, Denmark
HER-2 Polyclonal A0485 1:1,500 DAKO, Denmark
Ki-67 MIB-1 M7240 1:150 DAKO, Denmark
Lipolysis-related
HSL Polyclonal ab45422 1:100 Abcam, Cambridge, UK
PLIN1 Polyclonal ab61682 1:100 Abcam, Cambridge, UK
FABP4 Polyclonal ab13979 1:100 Abcam, Cambridge, UK
CPT-1 8F6AE9 ab128568 1:200 Abcam, Cambridge, UK
Acyl-CoA oxidase 1 Polyclonal ab128549 1:50 Abcam, Cambridge, UK
FASN EPR7466 ab128870 1:200 Abcam, Cambridge, UK
doi:10.1371/journal.pone.0137204.t001
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overexpressing and/or amplified; and triple negative breast cancer (TNBC) type: ER, PR, and
HER-2 negative.
Statistical analysis
Data were statistically processed using SPSS for Windows, version 12.0 (SPSS Inc., Chicago, IL,
USA). Correlation analysis of immunostaining results between primary breast cancer and met-
astatic breast cancer was calculated by the McNemar test. Student’s t- and Fisher’s exact tests
were used to examine any differences in continuous and categorical variables, respectively.
Corrected p-values and the Bonferroni method were used for multiple comparisons. Statistical
significance was assumed when P<0.05. Kaplan-Meier survival curves and log-rank statistics
were employed to evaluate time to tumor metastasis and time to survival. Multivariate regres-
sion analysis was performed using a Cox proportional hazards model.
Results
Baseline characteristics of patients
The baseline clinicopathologic characteristics of patients are summarized in Table 2. Among
149 patients with metastatic breast cancer, 39 (26.2%) had bone metastasis, 37 (24.8%) had
brain metastasis, 21 (14.1%) had liver metastasis, and 52 (34.9%) had lung metastasis. The rate
of ER positivity and PR positivity was higher in tumors of bone metastasis and liver metastasis
(p<0.001), while brain metastatic tumors had a higher rate of HER-2 positivity (p = 0.017).
The proportion of luminal A type tumors was significantly higher in bone metastasis and liver
Table 2. Basal clinicopathologic characteristics of patients with breast cancer metastasis according to metastatic site.
Parameters Total Bone metastasis Brain metastasis Liver metastasis Lung metastasis p-value
N = 149 (%) n = 39 (%) n = 37 (%) n = 21(%) n = 52 (%)
Age (yr, mean±SD) 52.0±10.5 53.1±9.8 53.2±12.0 53.8±11.0 49.7±9.5 0.287*
ER <0.001†
Negative 68 (45.6) 7 (17.9) 26 (70.3) 6 (28.6) 29 (55.8)
Positive 81 (54.4) 32 (82.1) 11 (29.7) 15 (71.4) 23 (44.2)
PR <0.001†
Negative 103 (69.1) 21 (53.8) 36 (97.3) 10 (47.6) 36 (69.2)
Positive 46 (30.9) 18 (46.2) 1 (2.7) 11 (52.4) 16 (30.8)
HER-2 0.017†
Negative 105 (70.5) 32 (82.1) 19 (51.4) 17 (81.0) 37 (71.2)
Positive 44 (29.5) 7 (17.9) 18 (48.6) 4 (19.0) 15 (28.8)
Ki-67 LI 0.001†
14 104 (69.8) 35 (89.7) 19 (51.4) 17 (81.0) 33 (63.5)
>14 45 (30.2) 4 (10.3) 18 (48.6) 4 (19.0) 19 (36.5)
Molecular subtypes <0.001†
Luminal A 58 (38.9) 28 (71.8) 3 (8.1) 12 (57.1) 15 (28.8)
Luminal B 24 (16.1) 5 (12.8) 8 (21.6) 3 (14.3) 8 (15.4)
HER-2 29 (19.5) 4 (10.3) 12 (32.4) 3 (14.3) 10 (19.2)
TNBC 38 (25.5) 2 (5.1) 14 (37.8) 3 (14.3) 19 (36.5)
Patient mortality 51 (34.2) 21 (53.8) 11 (29.7) 7 (33.3) 12 (23.1) 0.020†
* p-value was calculated by student’s t-test.
† p-value was calculated by Fisher’s exact test.
doi:10.1371/journal.pone.0137204.t002
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metastasis, while the rate of TNBC tumors was significantly higher in lung metastasis
(p<0.001).
Expression of lipid metabolism-related proteins in breast cancer
metastasis according to metastatic site
The expression of metabolism-related proteins according to metastatic site is summarized in
Table 3 and Table A in S1 File. In an analysis of lipid metabolism-related protein expression
according to metastatic site, the expression of ACOX1 (p = 0.009) and FASN (p = 0.007) varied
significantly according to metastatic site, with the highest expression rates in brain metastasis,
and the lowest expression rates in liver metastasis (Fig 1).
Correlation of expression of lipid metabolism-related proteins between
primary and metastatic breast cancer according to metastatic site
We investigated lipid metabolism-related protein expression in 36 cases of paired primary and
metastatic cancer. The results are shown in Table 4 and Table B in S1 File. FASN expression
was significantly different between primary and metastatic cancer (p = 0.008). In 8 (22.2%) of
the paired cases, the primary tumor was FASN-positive, while the metastatic tumor was FASN-
negative.
Correlation between pathologic factors and expression of lipid
metabolism-related proteins
In an analysis of pathologic factors and lipid metabolism-related protein expression, ER posi-
tivity correlated with HSL positivity (p<0.001). HER-2 positivity was associated with ACOX1
Table 3. Expression of metabolism-related proteins in the tumor cell compartment of breast cancer metastases according to metastatic site.
Parameters Total Bone metastasis Brain metastasis Liver metastasis Lung metastasis p-value*
N = 149 (%) n = 39 (%) n = 37 (%) n = 21(%) n = 52 (%)
HSL 0.199
Negative 102 (68.5) 23 (59.0) 25 (67.6) 13 (61.9) 41 (78.8)
Positive 47 (31.5) 16 (41.0) 12 (32.4) 8 (38.1) 11 (21.2)
PLIN1 0.388
Negative 147 (98.7) 39 (100.0) 37 (100.0) 20 (95.2) 51 (98.1)
Positive 2 (1.3) 0 (0.0) 0 (0.0) 1 (4.8) 1 (1.9)
FABP4 0.434
Negative 142 (95.3) 36 (92.3) 37 (100.0) 20 (95.2) 49 (94.2)
Positive 7 (4.7) 3 (7.7) 0 (0.0) 1 (4.8) 3 (5.8)
CPT-1A 0.381
Negative 124 (83.2) 30 (76.9) 33 (89.2) 19 (90.5) 42 (80.8)
Positive 25 (16.8) 9 (23.1) 4 (10.8) 2 (9.5) 10 (19.2)
Acyl-CoA oxidase 1 0.009
Negative 111 (74.5) 30 (76.9) 20 (54.1) 18 (85.7) 43 (82.7)
Positive 38 (25.5) 9 (23.1) 17 (45.9) 3 (14.3) 9 (17.3)
FASN 0.007
Negative 105 (70.5) 30 (76.9) 18 (48.6) 18 (85.7) 39 (75.0)
Positive 44 (29.5) 9 (23.1) 19 (51.4) 3 (14.3) 13 (25.0)
* p-value was calculated by Fisher’s exact test.
doi:10.1371/journal.pone.0137204.t003
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positivity (p = 0.005) and FASN positivity (p = 0.003). FASN expression varied according to
molecular subtype (p<0.001), with higher expression in HER-2 types and lower expression in
luminal A types and TNBCs (Fig 2).
Fig 1. Expression of lipid metabolism-related proteins in metastatic breast cancer according to metastatic site. There were significant differences in
the expression of lipid metabolism-related proteins according to metastatic site, with the highest expression of acyl-CoA oxidase 1 and FASN in brain
metastases.
doi:10.1371/journal.pone.0137204.g001
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Association between the expression of lipid metabolism-related proteins
and patient prognosis
A univariate analysis was performed to analyze the association between the expression of lipid
metabolism-related proteins and patient prognosis (Table 5). Factors associated with shorter
overall survival (OS) included PLIN1 positivity (p<0.001) and molecular subtype (TNBC,
p = 0.002). In an analysis according to metastatic site, FASN negativity (p = 0.039) was signifi-
cantly associated with shorter OS in brain metastases, and PLIN1 positivity (p = 0.005) corre-
lated with liver and lung metastasis (Fig 3).
In a multivariate analysis, higher KI-67 LI (Hazard ratio: 2.913, 95% CI: 1.313–6.462,
p = 0.009), and PLIN1 positivity (Hazard ratio: 4.979, 95% CI: 1.054–22.59, p = 0.043) showed
significant associations with shorter OS. The results are shown in Table 6.
Discussion
In this study, we observed a significant difference in lipid metabolism-related protein expres-
sion in metastatic breast cancers according to metastatic site. The expression of ACOX1
(p = 0.009) and FASN (p = 0.007) was higher in brain metastasis and lower in liver metastasis.
One possible explanation for this lies in differences in cancer cell characteristics according to
metastatic site. In our study, molecular subtype differed according to metastatic site, with a
higher rate of HER-2 type in brain metastasis, and a higher rate of luminal A type in liver
metastasis. In a previous study, FASN expression was reported to be associated with HER-2
expression [25]. Our study found an association between HER-2 positivity and FASN
Table 4. Correlation of expression of metabolism-related proteins between primary andmetastatic breast cancer according to metastatic site*.
Parameters Total Bone metastasis Brain metastasis Liver metastasis Lung metastasis
N = 36 (%) p-value n = 8 (%) p-value n = 5 (%) p-value n = 2 (%) p-value n = 21 (%) p-value
HSL 0.125 1.000 1.000 1.000 0.125
(+)! (+) 6 (16.7) 4 (50.0) 0 (0.0) 1 (50.0) 1 (4.8)
(+)! (-) 6 (16.7) 1 (12.5) 1 (20.0) 0 (0.0) 4 (19.0)
(-)! (+) 1 (2.8) 0 (0.0) 1 (20.0) 0 (0.0) 0 (0.0)
(-)! (-) 23 (63.9) 3 (37.5) 3 (60.0) 1 (50.0) 16 (76.2)
CPT-1A 0.500 1.000 1.000 N/A N/A
(+)! (+) 2 (5.6) 0 (0.0) 2 (40.0) 0 (0.0) 0 (0.0)
(+)! (-) 2 (5.6) 1 (12.5) 1 (20.0) 0 (0.0) 0 (0.0)
(-)! (+) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
(-)! (-) 32 (88.9) 7 (87.5) 2 (40.0) 2 (100.0) 21 (100.0)
Acyl-CoA oxidase 1 0.125 N/A 1.000 1.000 0.375
(+)! (+) 2 (5.6) 0 (0.0) 1 (20.0) 0 (0.0) 1 (4.8)
(+)! (-) 6 (16.7) 0 (0.0) 1 (20.0) 1 (50.0) 4 (19.0)
(-)! (+) 1 (2.8) 0 (0.0) 0 (0.0) 0 (0.0) 1 (4.8)
(-)! (-) 27 (75.0) 8 (100.0) 3 (60.0) 1 (50.0) 15 (71.4)
FASN 0.008 0.500 1.000 1.000 0.125
(+)! (+) 2 (5.6) 0 (0.0) 2 (40.0) 0 (0.0) 0 (0.0)
(+)! (-) 8 (22.2) 2 (25.0) 1 (20.0) 1 (50.0) 4 (19.0)
(-)! (+) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
(-)! (-) 26 (72.2) 6 (75.0) 2 (40.0) 1 (50.0) 17 (81.0)
* The data of FABP4 and PLIN1were removed because almost all cases were negative for FABP4 and PLIN1.
doi:10.1371/journal.pone.0137204.t004
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positivity, which is in agreement with the previous study. In a study on the molecular interac-
tion between HER-2 and FASN, it was reported that phosphorylation of FASN occurs when it
is in a complex with HER-2, which results in an increase in FASN enzymatic activity [26], sug-
gesting an axis between HER-2 and FASN that accelerates cancer cell proliferation, survival,
and metastasis. Another possible explanation could lie in the differing environments of the
metastatic sites. The brain, unlike other organs, produces energy by glycolysis using glucose,
not by mitochondrial oxidative phosphorylation, and thus the metabolic environment of the
brain is different from that of other organs. It has been reported that metabolism in the brain,
such as fatty acid oxidation, is different from that in other tissues [27]. Thus, this difference in
metabolic environments could be an explanation for the differences in metabolic features, but
further study would be required to evaluate this hypothesis.
Fig 2. Correlation between pathologic factors and expression of lipid metabolism-related proteins.
doi:10.1371/journal.pone.0137204.g002
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Our results showed that FASN expression was significantly different between primary and
metastatic tumors, and in most cases, the shift was from FASN-positivity in primary tumors to
FASN-negativity in metastatic tumors. Discordance between primary and metastatic tumors
has been also reported for ER, PR, and HER-2, which are the most important biomarkers of
breast cancer. HER-2 loss in 21–50% and HER-2 gain in 30% of metastatic tumors [8,28], ER
loss in 3.2–44% of metastatic tumors [29–31], and PR loss in 24% of metastatic tumors [31]
have been reported, whereas no gain of ER or PR in metastatic tumors have been reported. The
discordance in FASN expression between primary and metastatic tumors found in our study
Table 5. Univariate analysis of the association between expression levels of metabolism-related proteins in metastatic breast cancers and overall
survival by the log-rank test.
Parameters Total Bone metastasis Brain metastasis Liver metastasis Lung metastasis
N = 149 (%) n = 39 (%) n = 37 (%) n = 21 (%) n = 52 (%)
Mean
survival
(95% CI)
months
P-
value
Mean
survival
(95% CI)
months
P-
value
Mean
survival
(95% CI)
months
P-
value
Mean
survival
(95% CI)
months
P-
value
Mean
survival
(95% CI)
months
P-
value
HSL 0.497 0.762 0.259 0.634 0.672
Negative 105 (88–123) 81 (53–110) 95 (66–123) 83 (59–106) 125 (98–153)
Positive 112 (90–134) 78 (52–104) 98 (73–122) 62 (37–86) 140 (106–
174)
PLIN1 <0.001 N/A N/A 0.005 0.005
Negative 111 (96–125) N/A N/A 82 (63–102) 132 (108–
156)
Positive 14 (8–19) N/A N/A 11 (11–11) 17 (17–17)
FABP4 0.920 0.439 N/A N/A 0.746
Negative 109 (94–123) 83 (62–105) N/A N/A 130 (105–
154)
Positive 62 (36–89) 19 (14–24) N/A N/A 63 (26–99)
CPT-1A 0.880 0.714 N//A 0.208 0.660
Negative 111 (96–126) 85 (61–110) N/A 82 (61–102) 134 (109–
159)
Positive 66 (55–78) 59 (38–80) N/A 35 (35–35) 69 (51–87)
Acyl-CoA
oxidase 1
0.968 0.740 0.165 0.131 0.870
Negative 113 (96–130) 91 (62–120) 94 (61–127) 84 (64–104) 129 (103–
156)
Positive 100 (79–122) 78 (55–101) 92 (70–113) 26 (9–43) 124 (80–169)
FASN 0.127 0.553 0.039 0.914 0.473
Negative 101 (84–118) 85 (62–109) 83 (47–119) 78 (57–99) 124 (96–151)
Positive 91 (78–105) 53 (30–76) 96 (77–115) 60 (20–99) 76 (62–89)
Molecular
subtypes
0.002 N/A 0.034 N/A N/A
Luminal
A
102 (83–122) N/A 28 (0–58) N/A N/A
Luminal
B
138 (108–
168)
N/A 136 (106–
166)
N/A N/A
HER-2 140 (118–
163)
N/A 79 (60–97) N/A N/A
TNBC 51 (38–64) N/A 31 (22–39) N/A N/A
doi:10.1371/journal.pone.0137204.t005
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could be explained in a similar context as the aforementioned studies, but further study is
required to explore its clinical meaning.
In the present study, PLIN1 positivity of metastatic breast cancer was found to be an inde-
pendent prognostic factor. In previous studies, an association of PLIN1 and prognosis has
Fig 3. The impact of expression of lipid metabolism related proteins in metastatic breast cancer (a, b), liver metastasis (c), lungmetastasis (d) and
brain metastasis (e, f).
doi:10.1371/journal.pone.0137204.g003
Table 6. Multivariate analysis of patient prognoses in metastatic breast cancer.
Parameters Overall survival
Hazard ratio 95% CI P-value
ER negative vs. positive 0.992 0.226–4.360 0.992
PR negative vs. Positive 1.377 0.651–2.910 0.403
HER-2 negative vs. positive 0.493 0.146–1.667 0.255
Ki-67 LI 14 vs. >14 2.913 1.313–6.462 0.009
PLIN1 negative vs. positive 4.879 1.054–22.59 0.043
Non-TNBC vs. TNBC 2.815 0.548–14.47 0.215
Bold: shorter overall survival
doi:10.1371/journal.pone.0137204.t006
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rarely been reported. PLIN1 is a lipid droplet associated protein, and is reported to act as a
lipid droplet gate-keeper [19]. In breast cancer, lipid droplet formation is reported to be associ-
ated with prolonged breast cancer survival [32], so this could explain our result of PLIN1 posi-
tivity and its association with poor prognosis. But in this study, only a small proportion (1.3%)
of metastatic breast cancer had positive results and there may be limitations for a statistical
analysis. A further study involving a large volume of metastatic breast cancer may be needed.
The clinical significance of this study is the potential for lipid metabolism pathway inhibi-
tion to serve as a pharmaceutical treatment target. With respect to lipid metabolism, inhibition
of FASN has been reported to inhibit tumor growth [26,33–36]. In addition, small molecules
that inhibit fatty acid synthesis-related enzymes, such as acetyl-CoA carboxylase, are suggested
candidate for cancer therapy [37], a further study is needed to validate the possibility of lipid
metabolism molecules as treatment targets.
In our previous study, the expression of lipid metabolism-related proteins that were evalu-
ated in the present study had been investigated in primary breast cancers. The expression of
lipid metabolism-related proteins varied according to the molecular subtype defined by surro-
gate immunohistochemistry [38]. And the present study showed differences of lipid-metabo-
lism related proteins according to metastatic site. These results suggest the different lipid
metabolism of breast cancers in various conditions.
In conclusion, our study revealed differences in lipid metabolism-related protein expression
according to metastatic site, and found that the degrees of ACOX1 and FASN expression were
highest in brain metastasis, and lowest in liver metastasis.
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